Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01257451
First received: December 6, 2010
Last updated: December 14, 2012
Last verified: December 2012
  Purpose

This study will evaluate the efficacy and safety of vildagliptin 50 mg bid in elderly patients with Type 2 Diabetes Mellitus (T2DM).


Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: Vildagliptin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents)

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • To evaluate the proportion of vildagliptin treated patients achieving HbA1c reduction and/or proportion reaching investigator defined target HbA1c relative to placebo [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of vildagliptin in elderly patients with T2DM who are drug-naive or inadequately controlled with oral antidiabetic drugs (OADs) including physical exam, vital sign, hematology, chemistry and electrocardiogram. [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • To evaluate the proportion of vildagliptin treated patients achieving fasting plasma glucose (FPG) reduction relative to placebo [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • To assess the responder rates of patients treated with vildagliptin as compared to placebo [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Enrollment: 431
Study Start Date: December 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vildagliptin Drug: Vildagliptin
vildagliptin 50mg bid
Placebo Comparator: Placebo Drug: Placebo
Placebo 50mg bid

  Eligibility

Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age: ≥ 70 years inclusive at Visit 1.
  • patients with a confirmed diagnosis of T2DM
  • HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the investigator to be inadequately controlled
  • body mass index (BMI) in the range of 19-45kg/m2

Exclusion Criteria:

  • FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)
  • previous or current participation in any vildagliptin clinical study.
  • history of hypersensitivity to DPP-4 inhibitors.
  • concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
  • donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01257451

  Hide Study Locations
Locations
Belgium
Novartis Investigative Site
Buizingen, Belgium, 1501
Novartis Investigative Site
De Pinte, Belgium, 9840
Novartis Investigative Site
Genk, Belgium, 3600
Novartis Investigative Site
Mouscron, Belgium, 7700
Novartis Investigative Site
Nazareth, Belgium, 9810
Novartis Investigative Site
Oostham, Belgium, 3945
Novartis Investigative Site
Wichelen, Belgium, 9260
Bulgaria
Novartis Investigative Site
Blagoevgrad, Bulgaria, 2700
Novartis Investigative Site
Dimitrovgrad, Bulgaria, 6400
Novartis Investigative Site
Pleven, Bulgaria, 5800
Novartis Investigative Site
Plovdiv, Bulgaria, 4001
Novartis Investigative Site
Sofia, Bulgaria, 1431
Novartis Investigative Site
Varna, Bulgaria, 9002
Finland
Novartis Investigative Site
Lahti, Suomi, Finland, 15110
Novartis Investigative Site
Helsinki, Finland, 00180
Novartis Investigative Site
Oulu, Finland, FIN-90100
Germany
Novartis Investigative Site
Bamberg, Germany, 96050
Novartis Investigative Site
Beckum, Germany, 59269
Novartis Investigative Site
Berlin, Germany, 10115
Novartis Investigative Site
Falkensee, Germany, 14612
Novartis Investigative Site
Lichtenfels, Germany, 96215
Novartis Investigative Site
Lutherstadt Eisleben, Germany, 06295
Novartis Investigative Site
Magdeburg, Germany, 39112
Novartis Investigative Site
Mammendorf, Germany, 82291
Novartis Investigative Site
Münster, Germany, 48143
Novartis Investigative Site
Potsdam, Germany, 14469
Novartis Investigative Site
Sulzbach-Rosenberg, Germany, 92237
Novartis Investigative Site
Völlkingen, Germany, 66333
Novartis Investigative Site
Wetter, Germany, 58300
Slovakia
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia, 811 02
Novartis Investigative Site
Lubochna, Slovak Republic, Slovakia, 03491
Novartis Investigative Site
Kosice, Slovakia, 040 22
Novartis Investigative Site
Levice, Slovakia, 934 01
Novartis Investigative Site
Nové Zámky, Slovakia, 940 01
Novartis Investigative Site
Pie¿¿any, Slovakia, 92101
Novartis Investigative Site
Ruzomberok, Slovakia, 034 01
Spain
Novartis Investigative Site
Sanlúcar de Barrameda, Andalucía, Spain, 11540
Novartis Investigative Site
Centelles, Barcelona, Spain, 08540
Novartis Investigative Site
Alzira, Comunidad Valenciana, Spain, 46600
Novartis Investigative Site
Alicante, Spain, 03114
United Kingdom
Novartis Investigative Site
Truro, Cornwall, United Kingdom, TR1 3LJ
Novartis Investigative Site
Birmingham, United Kingdom, B9 5SS
Novartis Investigative Site
Exeter, United Kingdom, EX2 5DW
Novartis Investigative Site
Stevenage, United Kingdom, SG1 4AB
Novartis Investigative Site
Wiltshire, United Kingdom, SN15 2SB
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Corporation Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01257451     History of Changes
Other Study ID Numbers: CLAF237A23150, 2010-022658-18
Study First Received: December 6, 2010
Last Updated: December 14, 2012
Health Authority: United States: Food and Drug Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Bulgaria: Ministry of Health
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Ministry of Education and Research
Slovakia: State Institute for Drug Control
Spain: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:
Type 2 Diabetes Mellitus, Vildagliptin, Elderly Patients

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vildagliptin
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 26, 2014